Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

Q-SENSE-EDO Quantum-Coherent Optoelectronic Platform for Ultra-Early Detection of Oncometabolites

Coordinator
Fundacio Institut Catala D'investigacio Quimica, Spain
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335360

What the project is doing

In the project's own words, from its summary on CORDIS.

Early cancer detection remains a critical unmet medical need, as most diagnostic technologies only identify tumours after macroscopic lesions have formed. Mutations in isocitrate dehydrogenase (IDH1/2) produce the oncometabolite D-2-hydroxyglutarate (D-2HG), an early biochemical marker detectable in blood and urine. Current detection methods rely on chromatographic or enzymatic assays that require complex equipment, extensive sample preparation, and often struggle with sensitivity at very low concentrations.

Q-SENSE-EDO introduces a novel diagnostic approach based on quantum-engineered molecular sensing. Instead of measuring fluorescence intensity or relying on genomic amplification, the proposal aims to detect biological targets by observing changes in excited-state dynamics within molecular systems. The interaction between D-2HG and a specially engineered molecular interface is expected to cause measurable changes in excited-state lifetime, vibronic coherence, and non-radiative decay pathways.

These perturbations can be measured using time-resolved optoelectronic readouts, offering a physics-based sensing mechanism. The project builds on discoveries from the ERC Advanced Grant EXCITED, which demonstrated the ability to engineer molecular sensitizers with controlled excited-state dynamics and coherent photophysical behaviour. Q-SENSE-EDO will translate these findings into a proof-of-concept diagnostic platform by developing biofunctional quantum-coherent dyes, characterising their interaction with D-2HG using multidimensional time-resolved spectroscopy, and implementing a simplified lifetime-based classification model compatible with clinical instruments.

If successful, Q-SENSE-EDO will define quantum-state perturbation as a new biosensing principle, opening a technological frontier at the intersection of quantum chemistry, photonics, and biomedical diagnostics while establishing a robust intellectual property portfolio for quantum-enabled sensing technologies.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut Catala D'investigacio QuimicaTarragonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI